NeuroSense Therapeutics Ltd.
No SEC Form 4 filings for $NRSN in the last 30 days.
See all $NRSN insider activity →NeuroSense Therapeutics (NASDAQ: NRSN) says it has completed the Pre-NDS process with Health Canada for its ALS drug PrimeC and is targeting an NDS filing in early December 2026. Health Canada aligned on submission content and structure and raised no concerns. The NDS would be supported by Phase 2b PARADIGM results, including HR 0.35 (p=0.0037) median survival benefit.
NeuroSense Therapeutics (NASDAQ: NRSN) said its Phase 2b PARADIGM trial of PrimeC in ALS met the primary endpoint: at Day 180, TDP-43 fell vs placebo (p=0.0421), with differences sustained at Day 540 (p<0.001). The company also reported slower ALSFRS-R decline and a median survival benefit (HR 0.35, p=0.004), plus no new safety signals, and said FDA clearance was obtained for Phase 3.
Ben-Noon Alon (Chief Executive Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.
Over the past 7 days, alphai's AI scored 1 news story mentioning NRSN (NeuroSense Therapeutics Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent NRSN coverage spans financial news, insider activity and regulation.
Regulatory process alignment reduces timeline uncertainty for PrimeC’s Canadian submission, supporting a near-term sentiment bid while leaving approval risk unchanged.
Positive Phase 2b efficacy/biomarker readout increases probability of successful confirmatory Phase 3 and supports risk-on positioning in NRSN.
Insider buying by the CEO is modestly supportive, but the filing alone is unlikely to drive a large repricing without accompanying fundamentals.
Insider buying is modestly supportive sentiment, but it is not a fundamental catalyst by itself.
NeuroSense Therapeutics faces potential trading restrictions due to non-compliance with Nasdaq listing requirements. This could lead to increased volatility and downward pressure on the stock in the short term.
alphai scores every news story that mentions NRSN with an AI model for sentiment and relevance, and aggregates insider trades from NeuroSense Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NeuroSense Therapeutics (NASDAQ: NRSN) says it has completed the Pre-NDS process with Health Canada for its ALS drug PrimeC and is targeting an NDS filing in early December 2026. Health Canada aligned on submission content and structure and raised no concerns. The NDS would be supported by Phase 2b PARADIGM results, including HR 0.35 (p=0.0037) median survival benefit.
4 min readNeuroSense Therapeutics (NASDAQ: NRSN) said its Phase 2b PARADIGM trial of PrimeC in ALS met the primary endpoint: at Day 180, TDP-43 fell vs placebo (p=0.0421), with differences sustained at Day 540 (p<0.001). The company also reported slower ALSFRS-R decline and a median survival benefit (HR 0.35, p=0.004), plus no new safety signals, and said FDA clearance was obtained for Phase 3.
4 min readBen-Noon Alon (Chief Executive Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.
1 min readEisenberg Or (Chief Financial Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.
2 min readNeuroSense Therapeutics has received two notifications from Nasdaq indicating non-compliance with minimum bid price ($1.00 per share) and market value of listed securities ($35 million) requirements. These notifications do not immediately affect the trading of the company's shares. NeuroSense has 180 calendar days, until September 29, 2026, to regain compliance and is actively evaluating options to achieve this while focusing on long-term shareholder value.
3 min readNeuroSense Therapeutics Ltd. CTO Niva Russek-Blum has filed an initial ownership report detailing her equity holdings in the company. The report includes 36,000 fully vested options at an exercise price of $2.18, significant blocks of ordinary shares totaling over 250,000, and 10,000 restricted share units with varying vesting schedules. These disclosures provide transparency regarding the executive's stake in NeuroSense.
2 min readNeuroSense Therapeutics Ltd. (NRSN) Chief Technology Officer Niva Russek-Blum was granted 200,000 restricted Ordinary Shares as compensation. These shares, with a stated price of $0.00 per share, will vest in equal quarterly installments over a two-year period beginning March 26, 2026, contingent on her continued service. This grant increases her direct holdings to 467,953 Ordinary Shares and is subject to Section 102 of the Israeli Tax Ordinance for certain tax benefits.
2 min readNeuroSense Therapeutics Ltd.'s CEO, Alon Ben-Noon, has filed an initial ownership report detailing his significant holdings of ordinary shares and warrants. He directly owns over 3 million ordinary shares, along with additional blocks, and holds warrants to purchase over 100,000 ordinary shares with different exercise prices and expiration dates. The report also clarifies vesting schedules for restricted shares acquired in private placements.
2 min readNeuroSense Therapeutics (NASDAQ: NRSN) has granted its General Manager, Hagit Binder, 200,000 Ordinary Shares as a share-based compensation award. These restricted shares, which vest in equal quarterly installments over two years starting March 26, 2026, are part of the company's 2018 Share Incentive Plan. Following this grant, Binder directly holds 521,806 Ordinary Shares.
2 min readCAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
2 min read
